vs
AerSale Corp（ASLE）与CATALYST PHARMACEUTICALS, INC.（CPRX）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是AerSale Corp的1.7倍（$152.6M vs $90.9M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 5.9%，领先28.6%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -4.0%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $9.8M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 0.2%）
AerSale Corp总部位于美国佛罗里达州多拉市，是一家面向航空领域的全球供应商，主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材，并提供航空工程服务，同时该公司也是飞机机队回收协会的成员企业。
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
ASLE vs CPRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $90.9M | $152.6M |
| 净利润 | $5.4M | $52.7M |
| 毛利率 | 34.1% | 82.9% |
| 营业利润率 | 7.8% | 40.5% |
| 净利率 | 5.9% | 34.5% |
| 营收同比 | -4.0% | 7.6% |
| 净利润同比 | 99.7% | -5.8% |
| 每股收益（稀释后） | $0.10 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $90.9M | $152.6M | ||
| Q3 25 | $71.2M | $148.4M | ||
| Q2 25 | $107.4M | $146.6M | ||
| Q1 25 | $65.8M | $141.4M | ||
| Q4 24 | $94.7M | $141.8M | ||
| Q3 24 | $82.7M | $128.7M | ||
| Q2 24 | $77.1M | $122.7M | ||
| Q1 24 | $90.5M | $98.5M |
| Q4 25 | $5.4M | $52.7M | ||
| Q3 25 | $-120.0K | $52.8M | ||
| Q2 25 | $8.6M | $52.1M | ||
| Q1 25 | $-5.3M | $56.7M | ||
| Q4 24 | $2.7M | $55.9M | ||
| Q3 24 | $509.0K | $43.9M | ||
| Q2 24 | $-3.6M | $40.8M | ||
| Q1 24 | $6.3M | $23.3M |
| Q4 25 | 34.1% | 82.9% | ||
| Q3 25 | 30.2% | 84.7% | ||
| Q2 25 | 32.9% | 85.9% | ||
| Q1 25 | 27.3% | 87.3% | ||
| Q4 24 | 31.4% | 84.7% | ||
| Q3 24 | 28.6% | 85.0% | ||
| Q2 24 | 28.2% | 87.4% | ||
| Q1 24 | 31.8% | 87.3% |
| Q4 25 | 7.8% | 40.5% | ||
| Q3 25 | 4.0% | 44.7% | ||
| Q2 25 | 11.7% | 45.2% | ||
| Q1 25 | -10.1% | 44.8% | ||
| Q4 24 | 5.2% | 44.3% | ||
| Q3 24 | 2.4% | 39.6% | ||
| Q2 24 | -2.4% | 44.2% | ||
| Q1 24 | 5.2% | 27.5% |
| Q4 25 | 5.9% | 34.5% | ||
| Q3 25 | -0.2% | 35.6% | ||
| Q2 25 | 8.0% | 35.6% | ||
| Q1 25 | -8.0% | 40.1% | ||
| Q4 24 | 2.9% | 39.4% | ||
| Q3 24 | 0.6% | 34.1% | ||
| Q2 24 | -4.7% | 33.2% | ||
| Q1 24 | 6.9% | 23.6% |
| Q4 25 | $0.10 | $0.40 | ||
| Q3 25 | $0.00 | $0.42 | ||
| Q2 25 | $0.18 | $0.41 | ||
| Q1 25 | $-0.10 | $0.45 | ||
| Q4 24 | $0.05 | $0.44 | ||
| Q3 24 | $0.01 | $0.35 | ||
| Q2 24 | $-0.07 | $0.33 | ||
| Q1 24 | $0.12 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.4M | $709.2M |
| 总债务越低越好 | $1.3M | — |
| 股东权益账面价值 | $424.4M | $954.3M |
| 总资产 | $640.5M | $1.1B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
| Q4 25 | $4.4M | $709.2M | ||
| Q3 25 | $5.3M | $689.9M | ||
| Q2 25 | $5.7M | $652.8M | ||
| Q1 25 | $4.7M | $580.7M | ||
| Q4 24 | $4.7M | $517.6M | ||
| Q3 24 | $9.8M | $442.3M | ||
| Q2 24 | $4.3M | $375.7M | ||
| Q1 24 | $2.6M | $310.4M |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
| Q4 25 | $424.4M | $954.3M | ||
| Q3 25 | $417.1M | $920.2M | ||
| Q2 25 | $415.9M | $856.0M | ||
| Q1 25 | $406.5M | $794.3M | ||
| Q4 24 | $455.6M | $727.6M | ||
| Q3 24 | $451.5M | $660.9M | ||
| Q2 24 | $449.8M | $608.7M | ||
| Q1 24 | $452.0M | $561.4M |
| Q4 25 | $640.5M | $1.1B | ||
| Q3 25 | $646.3M | $1.1B | ||
| Q2 25 | $646.7M | $971.9M | ||
| Q1 25 | $646.1M | $908.9M | ||
| Q4 24 | $604.7M | $851.4M | ||
| Q3 24 | $601.5M | $772.0M | ||
| Q2 24 | $598.7M | $706.4M | ||
| Q1 24 | $571.7M | $646.7M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.4M | $44.9M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $44.9M |
| 自由现金流率自由现金流/营收 | 10.8% | 29.4% |
| 资本支出强度资本支出/营收 | 1.7% | 0.0% |
| 现金转化率经营现金流/净利润 | 2.11× | 0.85× |
| 过去12个月自由现金流最近4个季度 | $-29.1M | — |
8季度趋势，按日历期对齐
| Q4 25 | $11.4M | $44.9M | ||
| Q3 25 | $-8.9M | $32.4M | ||
| Q2 25 | $19.8M | $71.3M | ||
| Q1 25 | $-45.2M | $60.0M | ||
| Q4 24 | $37.5M | $70.9M | ||
| Q3 24 | $10.4M | $72.9M | ||
| Q2 24 | $-15.3M | $64.1M | ||
| Q1 24 | $-21.5M | $31.9M |
| Q4 25 | $9.8M | $44.9M | ||
| Q3 25 | $-9.8M | — | ||
| Q2 25 | $18.6M | $71.3M | ||
| Q1 25 | $-47.6M | — | ||
| Q4 24 | $32.3M | $70.8M | ||
| Q3 24 | $8.9M | $72.6M | ||
| Q2 24 | $-18.9M | $64.1M | ||
| Q1 24 | $-25.0M | $31.7M |
| Q4 25 | 10.8% | 29.4% | ||
| Q3 25 | -13.8% | — | ||
| Q2 25 | 17.3% | 48.6% | ||
| Q1 25 | -72.4% | — | ||
| Q4 24 | 34.0% | 49.9% | ||
| Q3 24 | 10.7% | 56.4% | ||
| Q2 24 | -24.6% | 52.3% | ||
| Q1 24 | -27.7% | 32.2% |
| Q4 25 | 1.7% | 0.0% | ||
| Q3 25 | 1.3% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 3.7% | 0.0% | ||
| Q4 24 | 5.6% | 0.1% | ||
| Q3 24 | 1.9% | 0.2% | ||
| Q2 24 | 4.7% | 0.0% | ||
| Q1 24 | 3.9% | 0.2% |
| Q4 25 | 2.11× | 0.85× | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | 2.31× | 1.37× | ||
| Q1 25 | — | 1.06× | ||
| Q4 24 | 13.89× | 1.27× | ||
| Q3 24 | 20.52× | 1.66× | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | -3.42× | 1.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
